An FDA advisory panel will review on May 2 Delcath's (DCTH) application for using its Hepatic...

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

An FDA advisory panel will review on May 2 Delcath's (DCTH) application for using its Hepatic Delivery System and melphalan hydrochloride to treat patients with unresectable ocular melanoma that is metastatic to the liver. Shares are +2.7% but down from earlier highs. (PR)